Sionna Therapeutics Inc (SION) Stock Price, Quote & News

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 819 2020

Website: www.sionnatx.com

Address:

21 Hickory Drive, Suite 500, Waltham, United States

d_risk Nov. 5 at 4:19 PM

$SION - Sionna Therapeutics, Inc. - 10Q - Updated Risk Factors SION’s updated 10-Q risk factors stress heightened uncertainty in clinical trial outcomes, regulatory hurdles, post-approval safety, manufacturing and IP challenges, evolving healthcare laws, and fierce competition—while streamlining or removing detail on orphan drug incentives, personnel, and operational growth risks. #Biotechnology #HealthcareLaws #ManufacturingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/SION/10-Q/2025-11-05

0 · Reply

shark1989 Oct. 27 at 2:05 PM

$SION Looking for a 5% push today!

0 · Reply

S_Franconi Oct. 22 at 1:11 PM

$SION Sionna’s ongoing clinical trials, including a Phase 1b trial for SION-451 combinations and a future Phase 2a trial for SION-719, are key catalysts that could validate their approach and potentially lead to significant market adoption. https://www.tipranks.com/news/ratings/buy-rating-for-sionna-therapeutics-innovative-cystic-fibrosis-treatments-with-promising-clinical-trials-ratings

1 · Reply

S_Franconi Oct. 22 at 12:17 PM

$SION 46 Watchers. 10/22/25

0 · Reply

topstockalerts Oct. 21 at 11:46 PM

Top Gainers PT2 $ATMV $BOF $SION $YDKG $NAUT

0 · Reply

topstockalerts Oct. 21 at 8:13 PM

Top Gainers PT2 $ATMV $BOF $SION $RANI $AGRZ

0 · Reply

extrodyne Oct. 21 at 8:00 PM

$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.

0 · Reply

patb99 Oct. 21 at 7:25 PM

$SION 😮

1 · Reply

DARKP00L Oct. 21 at 5:26 PM

$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas

0 · Reply

S_Franconi Oct. 21 at 5:14 PM

$SION https://apps.cff.org/trials/pipeline/

0 · Reply

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:00 AM EST - 11 days ago

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Oct 24, 2025, 1:15 PM EDT - 21 days ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Oct 21, 2025, 7:00 AM EDT - 25 days ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Oct 1, 2025, 4:05 PM EDT - 6 weeks ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Sep 10, 2025, 9:00 AM EDT - 2 months ago

Stock Picks From Seeking Alpha's August 2025 New Analysts

ASML CLF ENPH ESEA FRSH FTK GDX

Sep 8, 2025, 11:13 AM EDT - 2 months ago

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Jun 6, 2025, 11:00 AM EDT - 5 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 6 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 12, 2025, 7:00 AM EDT - 6 months ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Mar 20, 2025, 7:00 AM EDT - 8 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 9 months ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 10, 2025, 4:03 PM EST - 9 months ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 8, 2025, 2:30 AM EST - 10 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AARD AGH EPWK FBGL HCAI KRMN NPB

Feb 6, 2025, 7:51 PM EST - 10 months ago

Sionna Therapeutics Prices Upsized Initial Public Offering

Feb 1, 2025, 2:10 AM EST - 10 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE MTSR ODTX ODYS

Jan 24, 2025, 1:45 PM EST - 10 months ago

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Jan 17, 2025, 7:07 PM EST - 10 months ago

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Jan 17, 2025, 5:00 PM EST - 10 months ago

Sionna Therapeutics IPO Registration Document (S-1)

d_risk Nov. 5 at 4:19 PM

0 · Reply

shark1989 Oct. 27 at 2:05 PM

$SION Looking for a 5% push today!

0 · Reply

S_Franconi Oct. 22 at 1:11 PM

1 · Reply

S_Franconi Oct. 22 at 12:17 PM

$SION 46 Watchers. 10/22/25

0 · Reply

topstockalerts Oct. 21 at 11:46 PM

Top Gainers PT2 $ATMV $BOF $SION $YDKG $NAUT

0 · Reply

topstockalerts Oct. 21 at 8:13 PM

Top Gainers PT2 $ATMV $BOF $SION $RANI $AGRZ

0 · Reply

extrodyne Oct. 21 at 8:00 PM

$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.

0 · Reply

patb99 Oct. 21 at 7:25 PM

$SION 😮

1 · Reply

DARKP00L Oct. 21 at 5:26 PM

$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas

0 · Reply

S_Franconi Oct. 21 at 5:14 PM

$SION https://apps.cff.org/trials/pipeline/

0 · Reply

S_Franconi Oct. 21 at 5:11 PM

$SION Thank you Sion!

0 · Reply

Doozio Oct. 21 at 4:01 PM

$SION under radar 💎. Barring a faatch 💣. 🐒🍌🧠⏰♾️

0 · Reply

S_Franconi Oct. 21 at 2:53 PM

$SION Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-announces-initiation-precision-cf-phase-2a

0 · Reply

DARKP00L Oct. 21 at 11:14 AM

$SION 07:12 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a POC Trial Evaluating SION-719, NBD1 Stabilizer, When Added To Trikafta, Current Standard Of Care In CF; Topline Data Expected In Mid-2026 #tradeideas

0 · Reply

DARKP00L Oct. 21 at 11:13 AM

$SION 07:04 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a Proof-Of-Concept Trial Of SION-719 #tradeideas

0 · Reply

JarvisFlow Oct. 17 at 7:02 PM

Freedom Capital Markets has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Buy with a target price of 38.

1 · Reply

RunnerSignals Oct. 16 at 8:31 PM

Comeback Kings on the Move! $SLNO $FATE $SION hit the lows, bounced back, and finished strong!

0 · Reply

heyupikachu1821 Sep. 22 at 11:46 PM

$SION can anyone help me understand why SION is so expensive? I may be missing something, but it seems like they’re fairly early in development, and it seems odd that shares would be trading so high this early. This is not a knock against them or anything. I’m just trying to weigh the risk / reward opportunity here. And right now it seems like (near-term) it’s a high risk, low reward scenario???

5 · Reply

RunnerSignals Sep. 9 at 8:50 PM

$ATXS $DNTH $SION $SEZL $SDGR analysts see stars, but will these rockets launch? Strap in, it's gonna be a wild ride! https://stocksrunner.com/news/2025-09-09-unlocking-stocks-with-analyst-upgrades-and-short-term-upside-potential

0 · Reply

StocktwitsNews Sep. 8 at 5:32 AM

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar $SION https://stocktwits.com/news/equity/markets/sionna-short-squeeze-fades-as-raymond-james-backs-cystic-fibrosis-breakthrough-rbc-warns-treatments-set-high-bar/chwWVjjRdA4

0 · Reply

JarvisFlow Sep. 3 at 4:57 PM

Raymond James has updated their rating for Sionna Therapeutics ( $SION ) to Strong Buy with a price target of 45.

0 · Reply

Doozio Aug. 20 at 3:33 PM

$SION sneaking out on the DLO

0 · Reply

Market Cap	1.60B
Revenue (ttm)	0.00
Net Income (ttm)	-61.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,000
Avg Vol	302,294
Day's Range	N/A - N/A
Shares Out	44.63M
Stochastic %K	82%
Beta	N/A
Analysts	Strong Sell
Price Target	$40.40